['myelofibrosis']
['ruxolitinib', 'vismodegib']

        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of primary MF, post-polycythemia vera MF, or
             post-essential thrombocythemia MF, according to the 2008 revised World Health
             Organization criteria

          -  Intermediate-1, intermediate-2, or high-risk according to the IWG-MRT Dynamic
             International Prognostic Scoring System

          -  Life expectancy >= 6 months

          -  Peripheral blood blast count of less than (<) 10%

          -  Palpable splenomegaly of greater than (>) 5 centimeters (cm) below the left costal
             margin

          -  Eastern Cooperative Oncology Group performance status of 0 to 2

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Prior treatment with a Hedgehog or Janus kinase pathway inhibitor

          -  Treatment with strong cytochrome P450 3A4 inhibitors/inducers within 28 days prior to
             Day 1

          -  Prior therapy for the treatment of intermediate- or high-risk MF including
             chemotherapy, interferon, thalidomide, busulfan, lenalidomide, anagrelide, or
             androgens within 28 days prior to Day 1

          -  Prior splenectomy or splenic irradiation

          -  Inadequate bone marrow reserve

          -  Participants with any history of platelet counts of < 50,000/mccL or ANC of < 500/mL,
             except during treatment for myeloproliferative neoplasm or treatment with cytotoxic
             therapy for any other reason

          -  Planned allogeneic bone marrow transplant during the study
      